Actively Recruiting
Biologically-Adapted, Dose-Escalated Accelerated Radiotherapy for Ewing Sarcoma (BEAR)
Led by Mayo Clinic · Updated on 2026-06-04
141
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of biologically-adapted, dose-escalated radiotherapy based on tumor size and specific tumor characteristics in patients with Ewing sarcoma. This cancer treatment study explores how higher doses of radiotherapy, delivered over shorter periods (hypofractionated), might better control the disease at the primary tumor site, especially in patients with larger tumors. The trial also studies the role of biomarkers by analyzing blood and tumor samples to predict disease status and cancer recurrence. Patients may receive standard chemotherapy every two weeks for at least three cycles before starting radiotherapy. Depending on tumor size and characteristics, participants receive either hypofractionated or conventional dose-escalated radiotherapy, or standard radiotherapy, delivered daily except weekends and holidays, with 25 to 36 treatment sessions. Some patients may undergo definitive surgical tumor removal and consolidation chemotherapy after radiotherapy. Blood samples and imaging tests such as CT, PET/CT, and MRI are collected throughout the study. During the trial, participants undergo regular assessments including blood sample collection and various imaging scans to monitor disease progression and treatment effects. Researchers measure outcomes such as reduction in local tumor failure for large tumors over up to two years, and track adverse events, event-free survival, time to progression, and overall survival for up to one year after local therapy. The study involves ongoing monitoring of health status and disease control during and after treatment.
CONDITIONS
Brief Title
Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histological confirmation of Ewing sarcoma or Ewing-like sarcoma treated per Ewing treatment paradigms
- Age 2 years or older
- Lansky or Karnofsky performance status of 70 or higher
- Ability to provide written informed consent and complete questionnaires with or without assistance
- Willingness to provide blood samples for research
- Willingness to provide biopsy sample if tumor size is 8 cm or larger
You will not qualify if you...
- Prior chemotherapy or radiotherapy that interferes with current treatment or outcome measurement
- Use of investigational agents that interfere with current treatment or outcome measurement
- Active malignancy within 1 year prior to registration interfering with treatment or outcomes
- Severe co-morbid systemic illness or other diseases interfering with treatment or outcomes
- Active uncontrolled systemic infection, symptomatic heart failure, unstable angina, cardiac arrhythmia, psychiatric illness, or social situations limiting adherence
- Pregnancy or nursing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Variable treatment duration depending on chemotherapy cycles, radiotherapy fractions, and surgery timing
Participants receive chemotherapy every 2 weeks for at least 3 cycles prior to radiotherapy. They then undergo hypofractionated or conventional dose-escalated or standard radiotherapy daily, excluding weekends and holidays, for 25 to 36 treatment fractions depending on the cohort, in the absence of disease progression or unacceptable toxicity. Participants may also undergo definitive surgical resection depending on cohort assignment. Consolidation chemotherapy may be given after completion of radiotherapy and/or surgery. Blood samples are collected throughout treatment. Imaging such as CT, PET/CT, and MRI may be performed at the treating clinician’s discretion.
Chemotherapy visits every 2 weeks for at least 3 cycles; daily radiotherapy visits excluding weekends and holidays for up to 7 weeks; additional visits for surgery and consolidation chemotherapy as applicable
Duration - Up to 1 year after completion of local therapy
After completing local therapy, participants are monitored for up to 1 year to assess safety, event-free survival, time to progression, and overall survival. Blood samples and imaging may continue as clinically indicated.
Periodic visits as scheduled by the study team
Trial Site Locations
Total: 2 locations
1
Mayo Clinic in Arizona
Phoenix, Arizona, United States, 85054
Not Yet Recruiting
2
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
C
Clinical Trials Referral Office
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here